FATE Fate Therapeutics Inc.

14.75
+0.62  (+4%)
Previous Close 14.13
Open 14.16
Price To Book 7.56
Market Cap 964,443,353
Shares 65,385,990
Volume 653,429
Short Ratio
Av. Daily Volume 822,812
Stock charts supplied by TradingView

NewsSee all news

  1. Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

    SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  2. Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  3. Fate Therapeutics Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  4. Fate Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  5. Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data released at SITC November 10, 2017.
FATE-NK100
Acute myelogenous leukemia (AML)
Phase 2 data due 2020.
ProTmune - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
Phase 1 trial initiated February 2018.
NK100 - DIMENSION
Solid tumors
Phase 1 dosing commenced February 2019.
FT500
Soild tumors

Latest News

  1. Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

    SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune

  2. Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  3. Fate Therapeutics Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  4. Fate Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular

  5. Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune